News & Updates

The incidence of dermatofibrosarcoma protuberans (DFSP) is two times higher among Black than White individuals, reports a study.

Hidradenitis suppurativa (HS) poses increased risk of adverse maternal and offspring outcomes not only during the peripartum period but also in the long term, according to a study.

A post hoc analysis of a phase IV study presented at EADV 2024 underscores the ability of the fourth-generation retinoid trifarotene to reduce atrophic acne scars across all skin types, with a more profound effect among individuals with higher baseline acne and acne scarring severity.

Older adults with a history of nonmelanoma skin cancer (NMSC) appear to have fewer incident fractures, according to a study.

New drug applications approved by US FDA as of 1-15 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 16-30 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In the phase III head-to-head DELTA FORCE trial, topical delgocitinib cream gains the upper hand over oral alitretinoin – the only oral systemic therapy approved for the treatment of severe chronic hand eczema (CHE) in adults with inadequate response to topical corticosteroids.